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Dear Editor,
Uridine diphosphate-glucuronosyltransferase 1A (UGT1A1), an 
enzyme encoded by the UGT1A1 gene on chromosome 2q37, 
is the major bilirubin-conjugating enzyme [1, 2]. Variants in the 
promoter and coding regions of UGT1A1 affect the enzyme ac-
tivity of UGT1A1, leading to unconjugated hyperbilirubinemia 
disorders, including Gilbert syndrome (GS), Crigler-Najjar syn-
drome type I (CNI), and Crigler-Najjar syndrome type II (CNII). 
Variant frequencies show inter-ethnic differences [3, 4]. Reports 
on the spectrum of variants in Korean patients with hyperbiliru-
binemia are limited thus far; they are mostly based on a small 
number of patients evaluating a few mutational hotspots [5, 6]. 
We retrospectively investigated the spectrum of UGT1A1 varia-
tion in a larger study population to examine the allele distribu-
tion in Korean patients with unconjugated hyperbilirubinemia. 
We collected clinical data of 81 patients with hyperbilirubine-
mia who underwent UGT1A1 genotyping between April 2013 
and March 2019 in Gangnam Severance Hospital, Seoul, Ko-
rea. For comparison, we retrieved allele frequencies of 1,722 Ko-
rean subjects from the Korean Reference Genome database 
(KRGDB, http://coda.nih.go.kr/coda/KRGDB/index.jsp), and of 
80 Chinese and 71 Japanese healthy subjects from published 
data [7, 8]. For association analysis of genotypes and total bili-
rubin (TB) levels, we retrieved allele frequencies and laboratory 
data from a published study [9]. This study was approved by the 
Institutional Review Board of Yonsei University Health System, 
Gangnam Severance Hospital (IRB-2019-0188-001). The need 
for informed consent of the participants for reviewing medical 
records was waived on the condition that the research involves 
no more than minimal risk to the patients and the patient’s pri-
vacy was thoroughly protected. 
The promoter region, including the TATA box and all five ex-
ons with flanking introns of UGT1A1, were PCR-amplified in a 
3500 Dx Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA) using an in-house method. The sequences were com-
pared with a UGT1A1 reference sequence (accession number: 
NM_000463.2) registered in the National Center for Biotechnol-
ogy Information database (https://www.ncbi.nlm.nih.gov). Two 
independent experts evaluated the variants, and the haplotype 
was annotated according to UGT1A1 allele nomenclature guide-
lines (https://www.pharmacogenomics.pha.ulaval.ca/wp-con-
tent/uploads/2015/04/UGT1A1-allele-nomenclature.html).
Statistical analyses were conducted using Analyse-it v.5.11 
Method Evaluation edition (Analyse-it Software, Ltd., Leeds, UK). 
Allele frequencies in the control and study groups were com-
pared using Fisher’s exact test. Results were considered signifi-
cant at P <0.05.
We detected nine variants in this study (Table 1). All variants 
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  1 Wild Wild HS (1) 69.08 148 13.34±3.42
  2 TA6/7 p.Gly71Arg +/- ; p.Ala61Gly +/– GS (1) 20.52 - -
  3 Wild p.Gly71Arg +/+ GS (3) 25.65±2.91   18 23.60±6.16
  4 TA6/7 p.Pro229Gln +/– GS (2) 28.22±1.20 - -
  5 TA7/7 p.Pro229Gln +/+ GS (1) 30.78 - -
  6 TA6/7 Wild GS (3) 34.54±15.56   49 17.27±5.64
  7 TA7/7 p.Pro364Leu +/– GS (2) 35.91±7.18 - -
  8 Wild p.Gly71Arg +/– GS (4) 34.71±12.31   83 15.90±3.25
  9 TA6/7 p.Gly71Arg +/– GS (14) 40.01±24.45   19 24.62±5.13
10 TA7/7 Wild GS (12) 46.68±17.10     7 33.17±4.10
11 Wild p.Gly71Arg +/– ; p. Pro364Leu +/– GS (1) 61.56 - -
12 Wild p.Gly71Arg +/– ; p.Tyr486Asp +/+ CNII (1) 75.24 - -
13 Wild p.Gly71Arg +/+ ; p.Tyr486Asp +/+ CNII (1) 79.86 - -
Abbreviations: +/–, heterozygous variant; +/+, homozygous variant; GS, Gilbert’s syndrome; CNII, Crigler-Najjar syndrome II; HS, hereditary spherocytosis; 
TB, total bilirubin.
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Promoter c.-64G>C *81 - 0.037 (6/0) - - 0.036 0.832 rs873478
Promoter c.-41_-40dupTA *28 - 0.438 (31/20) 0.144 (21/1) 0.113 (12/2) 0.200 <0.0001 rs34983651
Intron 1 c.864+2T>C Novel - 0.006 (1/0) - - 0.000 0.045 rs772088902
Exon 1 c.182C>G Novel p.Ala61Gly 0.006 (1/0) - - 0.000 0.045 rs1273237448
Exon 1 c.211G>A *6 p.Gly71Arg 0.315 (31/10) 0.169 (23/2) 0.183 (20/3) 0.173 <0.0001 rs4148323
Exon 1 c.686C>A *27 p.Pro229Gln 0.037 (6/0) 0.013 (2/0) - 0.014 0.030 rs35350960
Exon 4 c.1091C>T *73 p.Pro364Leu 0.031 (5/0) 0.006 (1/0) - 0.013 0.077 rs34946978
Exon 5 c.1456T>G *7 p.Tyr486Asp 0.031 (1/2) 0.000 (0/0) 0.014 (2/0) 0.001 <0.0001 rs34993780
Exon 5 c.1352C>T N/A p.Pro451Leu 0.006 (1/0) - - 0.001 0.241 rs114982090
Values in bold indicate statistical significance.
*Korean Reference Genome database (http://coda.nih.go.kr/coda/KRGDB/index.jsp); †P values for comparison between Korean patients with hyperbilirubi-
nemia and Korean control subjects were calculated based on Fisher’s exact test.
identified in exons were missense variants, and two novel vari-
ants (c.864+2T>C and p.Ala61Gly) were detected. The most 
frequent allele was UGT1A1*28, with a frequency of 43.8% 
(71/162), followed by the UGT1A1*6 allele, with a frequency of 
31.5% (51/162). The frequency of the wild-type allele was 4.9% 
(8/162) in the 81 hyperbilirubinemia patients. The frequencies 
of the UGT1A1*28, UGT1A1*6, UGT1A1*27, and UGT1A1*7 
alleles were significantly different between patients and the Ko-
rean control group. 
Table 2 shows the UGT1A1 genotypes detected in 46 patients 
with available clinical data. Homozygous UGT1A1*7 alleles with 
homozygous or heterozygous UGT1A1*6 alleles were detected 
in two CNII patients only, and these patients showed the highest 
TB levels (79.87 µmol/L and 75.24 µmol/L, respectively). Forty-
three GS patients were grouped into 10 different UGT1A1 geno-
types. Heterozygous or homozygous UGT1A1*28 (TA6/7, TA7/7) 
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(58.1%, 50/86) and heterozygous or homozygous UGT1A1*6 
(30.2%, 26/86) were frequently identified in GS patients. 
In this study, UGT1A1*28 and UGT1A1*6 were the most fre-
quent alleles. While UGT1A1*6 is the most frequent allele in 
East Asian hyperbilirubinemia patients [3], UGT1A1*28 was the 
most frequent allele (44.3%, 51/81) in this study. Two CNII pa-
tients were homozygous for the UGT1A1*7 allele in combina-
tion with the UGT1A1*6 allele. Homozygous genotype of the 
UGT1A1*7 allele has been previously reported in CNII cases [5- 
8]. Homozygous UGT1A1*7 allele has a strong association with 
CNII in the Asian population [6], in line with our results.
Two patients carried novel variants. A 57-year-old female pa-
tient had a c.864+2T>C variant combined with a heterozygous 
UGT1A1*28 allele. c.864+2T>C is a variant at the splice-donor 
site at the 5´ end of intron 1. An adjacent splice-donor site vari-
ant, c.864+1G>C, has been reported in a CNI patient in a ho-
mozygous genotype, and this variant is expected to induce splicing 
at a cryptic site [10]. Therefore, we believe that the c.864+2T>C 
variant contributed to the medical condition of the patient. A 
five-year-old male patient had a c.182C>G variant combined 
with compound heterozygous UGT1A1*6 and UGT1A1*28 al-
leles. c.182C>G is a missense variant in exon 1. Further evi-
dence based on more patient cases and investigation of the ef-
fects of these variants on enzyme activity are needed to assign a 
pathogenic role to these two novel variants; we interpreted these 
variants as variant of uncertain significance according to Ameri-
can College of Medical Genetics guidelines [11]. 
In conclusion, from the spectrum of UGT1A1 variations, UG-
T1A1*28 and *6 alleles tend to be prevalent in Korean patients 
with unconjugated hyperbilirubinemia and the UGT1A1*28 al-
lele tends to be more prevalent than in other Asian populations. 
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